Neurological Disorder Diagnostics Treatment Market Size, Share, Opportunities, And Trends By Type of Disorder (Neurodegenerative Disorders, Neuromuscular Disorders, Spinal Disorders, Peripheral Nerve Disorder), By Technology (Neurodegenerative Disorders, Neuromuscular Disorders, Spinal Disorders, Peripheral Nerve Disorder), By End User (Hospitals & Clinics, Diagnostic Centers, Others), And By Geography - Forecasts from 2025 To 2030

Neurological Disorder Diagnostics Treatment Market Size:

The Neurological disorder diagnostics treatment market is expected to grow at a CAGR of 4.76%, reaching a market size of US$18.903 billion in 2030 from US$14.340 billion in 2025.

Neurological Disorder Diagnostics Treatment Market Trends:

Neurological disorders are conditions that affect nervous system functioning including the brain, spinal cord and nerves. The disorder includes neurodegenerative conditions like Alzheimer's, multiple sclerosis, and Parkinson’s disease; neuromuscular conditions such as muscular dystrophy, and amyotrophic lateral sclerosis; Spine conditions like Spina Bifida, spinal cord injury, spinal muscular atrophy and peripheral nerve conditions like peripheral neuropathy, carpel tunnel syndrome among some other diseases. 

The neurological disorder diagnostics market consists of all the tools, techniques, devices, products, and services used to diagnose neurological disorders, such as Alzheimer's, migraines, and sclerosis, including magnetic resonance imaging, computed tomography, neuroimaging biomarkers, ultrasound systems, blood & cerebrospinal fluid tests for biomarkers, genetic testing, wearable and portable devices and software for analyzing data among others. Hospitals, clinics, and diagnostic centres are covered under the market. 

Several factors are contributing to the cause of growing of the neurological disorder diagnostic market. There is a growing prevalence of neurological diseases like Alzheimer's, dementia, Parkinson’s disease and others along with the increasing number of brain injuries due to rising cases of accidents, causing the market demand to rise. Also, governments and NGOs along with other institutions are creating awareness among people to prioritize early screening of neurological health, propelling the demand for early diagnosis. Further, the increased investment in research and development has led to advancement in diagnostics technology and processes, resulting in market expansion. This is further aggravated by the increasing adoption of artificial intelligence and machine learning technologies that is boosting the market growth by offering more accurate data and data analysis. Moreover, the increasing healthcare investment by the government, particularly driven by emerging countries is offering a boost to market growth. Thus, the market is expanding with the opportunities for expansion and innovation. 

What are the Neurological Disorder Diagnostics Treatment Market Drivers?

• Rising Prevalence of neurological disorders 

The world is witnessing a substantial rise in the number of neurological disorders due to variety of reasons such as the changing lifestyle characterised by stress, mental health issues, reduced physical activity and over-reliance on digital technology; an ageing population; increasing pollutions and toxins in the environment among other reasons. It is leading to increased cases of diseases like Alzheimer's, Parkinson disease etc, growing the demand for neurological disorder diagnostics tools and techniques. It is evident from the released by the Alzheimer’s Association which states that roughly 4.8 million Americans aged 65 have dementia due to the Alzheimer disease. A total of 6.9 million people in America has dementia. 

• Increasing advancement in technology for diagnosing neurological disorder

Neurological disorders are witnessing significant advancements in diagnostic technologies and processes leading to growth in the market. These innovations are addressing previously unmet needs by enabling more efficient and accurate diagnoses such as advancement in technologies like MRI, CT scans, PET scans, fMRI, Genetic testing and others thereby improving patient outcomes and meeting the rising demand for precise and timely neurological care. For example, advancement in gene therapy such as vector targeting through capsid modifications is increasing efficiency of transduction and delivering it to the wider area. Also, the emerging technologies like artificial intelligence and machine learning is being used to analyze the complex data sets for fast and accurate detection of the disorders such as AI is being leveraged in MRI to detect subtle abnormalities in conditions like brain tumours, strokes etc. 

Neurological Disorder Diagnostics Treatment Market Restraints:

• The high cost of advanced diagnostic techniques limits its market expansion to low- and middle-income countries 

Neurological disorder diagnostic techniques, tools, and devices are costly, and the advanced tools and techniques are highly expensive. An average MRI scan rangess from $1600 to $8400 in the US depending on the provider and other factor. Also, the maintenance and operational cost of tools and machines along with the cost associated with skilled professionals needed for the diagnosis process makes the overall cost expensive for the masses, more particularly for those people who belong to low and middle income. Countries of low and middle income lacks the necessary health infrastructure including for neurological disorder diagnostics, limiting the market expansion. Patients as well as hospitals & diagnostic centers find it hard to afford these advanced techniques, thus limiting access to a large chunk of the population. There is a need for cost-effective alternatives along with increased investment by governments and private players. 

Segment Analysis of the Neurological Disorder Diagnostics Treatment Market:

• By Application, hospitals and clinics will continue to hold the largest segment

By end-user, the neurological disorder diagnostics market is segmented into hospitals & clinics, diagnostic centers and others. During the forecast period, hospitals and clinics will continue to dominate the market. 

Hospitals and clinics are the largest end-users of neurological disorder diagnosis as hospitals are crucial for healthcare infrastructure and play a central role in patient care. These healthcare facilities require advanced diagnostic tools to accurately identify and treat conditions like Alzheimer's, Parkinson's, epilepsy etc, As these advanced infrastructures for diagnosis are expensive and need infrastructure, thus, hospitals are often equipped with diagnostic equipment and skilled professionals, and their capacity for conducting the diagnosis, making hospitals & clinics to hold the largest market share. 

What key geographical trends are shaping the Neurological Disorder Diagnostics Treatment Market?

• Asia-Pacific will be the fastest-growing region during the forecast period

The neurological disorder diagnostics market is segmented by geography into North America, South America, Europe, the Middle East and Africa, and Asia-Pacific. During the forecast period, Asia-Pacific will be the fastest-growing region in the neurological disorder diagnostics market. Meanwhile, North America will continue dominating the market in the coming years. Also, Europe will be having significant market share in the forecast period.

The Asia Pacific region will be the fastest-growing market during the forecast period. This robust growth in the region is attributed to the growing economies of Asia-Pacific like China, South Korea, and India which is driving continued healthcare infrastructure development in the region, resulting in growth in associated markets like the neurological disorder diagnostic market. Also, the increasing prevalence of neurological disorders is driving the demand the diagnostics thus, propelling the market growth. 

Meanwhile, North American market is estimated to hold a significant market share in the neurological disorders diagnostics market. This dominance is driven by the advanced healthcare infrastructure in countries like the United States. Also, the high prevalence of neurological disorders is driving the market demand for neurological disorders such as 6.9 million dementia patient from Alzheimer in 2024. Further, significant investment is being made by the government and private players is driving its continued expansion in the region. 

Recent Developments in the Neurological Disorder Diagnostics Treatment Market:

• In April 2024, neuroClues®, a medtech company specializing in neurodegenerative disease diagnostics, has successfully closed a €5 million funding round, bringing its total funding to €12 million. The investment will support product development and expansion into European and North American markets.
• In November 2024, PTC Therapeutics announced the FDA's accelerated approval of KEBILIDI™, a gene therapy for AADC deficiency, the first gene therapy administered directly to the brain.KEBILIDI received accelerated approval based on the safety and clinical efficacy findings in the ongoing global clinical trial of the gene therapy. 

 

Neurological Disorder Diagnostics Treatment Market Scope:

Report Metric	Details
Neurological Disorder Diagnostics Treatment Market Size in 2025	US$14.340 billion
Neurological Disorder Diagnostics Treatment Market Size in 2030	US$18.903 billion
Growth Rate	CAGR of 4.76%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Type of Disorder Technology End-User Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the Neurological Disorder Diagnostics Treatment Market	Emerson Electric Co. Spirax Sarco Limited Thermax Limited Velan, Inc. Watson McDaniel
Customization Scope	Free report customization with purchase

 

The Neurological Disorder Diagnostics Treatment Market is analysed into the following segments:

• By Type of Disorder
  • Neurodegenerative Disorders
  • Neuromuscular Disorders
  • Spinal Disorders
  • Peripheral Nerve Disorder
• By Technology
  • Imaging Techniques
  • In Vitro Diagnostic Techniques
• By End-User
  • Hospitals & Clinics
  • Diagnostic Centers
  • Others  
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • Australia
    • India
    • Indonesia
    • Thailand
    • Others

Our Best-Performing Industry Reports:

• Blood Pressure Monitoring Devices Market
• Smart Medical Device Market
• Refurbished Medical Equipment Market

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. CXO Perspective

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View 

5. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY TYPE OF DISORDER

5.1. Introduction

5.2. Neurodegenerative Disorders

5.3. Neuromuscular Disorders

5.4. Spinal Disorders

5.5. Peripheral Nerve Disorder

6. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY TECHNOLOGY

6.1. Introduction

6.2. Imaging Tecxhniques

6.3. In Vitro Diagnostic Techniques

7. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY END-USER

7.1. Introduction

7.2. Hospitals & Clinics

7.3. Diagnostic Centers

7.4. Others  

8. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Type of Disorder

8.2.2. By Technology

8.2.3. By End-User

8.2.4. By Country

8.2.4.1. USA

8.2.4.2. Canada

8.2.4.3. Mexico

8.3. South America

8.3.1. By Type of Disorder

8.3.2. By Technology

8.3.3. By End-User

8.3.4. By Country

8.3.4.1. Brazil

8.3.4.2. Argentina

8.3.4.3. Others

8.4. Europe

8.4.1. By Type of Disorder

8.4.2. By Technology

8.4.3. By End-User

8.4.4. By Country

8.4.4.1. United Kingdom

8.4.4.2. Germany

8.4.4.3. France

8.4.4.4. Spain

8.4.4.5. Others

8.5. Middle East and Africa

8.5.1. By Type of Disorder

8.5.2. By Technology

8.5.3. By End-User

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.2. UAE

8.5.4.3. Others

8.6. Asia Pacific

8.6.1. By Type of Disorder

8.6.2. By Technology

8.6.3. By End-User

8.6.4. By Country

8.6.4.1. China

8.6.4.2. Japan

8.6.4.3. South Korea

8.6.4.4. Australia

8.6.4.5. India

8.6.4.6. Indonesia

8.6.4.7. Thailand

8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. GE Healthcare

10.2. Siemens Healthcare

10.3. FUJIFILM Holdings Corporation

10.4. Koninklijke Philips N.V.

10.5. Thermo Fisher Sxcientific Inc.

10.6. Masimo

10.7. Medtronic

10.8. Abbott Laboratories

GE Healthcare

Siemens Healthcare

FUJIFILM Holdings Corporation

Koninklijke Philips N.V.

Thermo Fisher Sxcientific Inc.

Masimo

Medtronic

Abbott Laboratories